|  |
| --- |
| May 29, 2013 |
|  |
| Barbara Müller  Head of Corporate Press  Phone +49 201 177-3423  Fax +49 201 177-3030  barbara.mueller@evonik.com |
|  |
| Evonik Industries AG  Rellinghauser Straße 1-11  45128 Essen Germany  Phone +49 201 177-01  Fax +49 201 177-3475  www.evonik.de  **Supervisory Board**  Dr. Werner Müller, Chairman  Executive Board  Dr. Klaus Engel, Chairman  Dr. Wolfgang Colberg, Dr. Thomas Haeberle,  Thomas Wessel, Patrik Wohlhauser, Dr. Dahai Yu  Registered office Essen  Registered court  Essen local court  Commercial registry B 19474  VAT ID no. DE 811160003 |

**Changes in the Executive Board of Evonik Industries AG**

The executive committee of the supervisory board of Evonik Industries AG has proposed to the supervisory board to give its consent to the termination of the board position of Dr Wolfgang Colberg (53) as chief financial officer in best mutual agreement with effect to September 30, 2013. Dr Colberg is the chief financial officer of Evonik since April 1, 2009.

Moreover, the executive committee of the supervisory board of Evonik Industries AG has proposed today to the supervisory board to appoint Ms Ute Wolf (45) as chief financial officer with effect from October 1, 2013. Ms Wolf is head of finance of Evonik since January 1, 2006.

The final decision is to be made by the supervisory board of Evonik Industries AG which is expected to resolve on this on June 21, 2013.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.